Head-to-head evidence
AZD8630 vs tezepelumab
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Asthma
Shared mechanism: TSLP · full Asthma pipeline
AZD8630
Developed by AstraZeneca and partners
NCT06529419 · Phase 2 · completed
The study randomized 537 participants across three AZD8630 dose groups and placebo, with participants, care providers, investigators, and outcome assessors quadruple-blinded. Its primary endpoint was a clinical exacerbation-related measure, but the primary comparison cannot yet be judged because results have not been reported.
tezepelumab · Tezspire
Marketed by AstraZeneca and partners
NCT03347279 · Phase 3 · completed
This was a large randomized, double-blind, placebo-controlled trial with 1,061 participants. Both prespecified primary clinical endpoints were met: tezepelumab significantly reduced annual asthma exacerbations overall and in the lower-eosinophil subgroup, with p<0.001 for each comparison.
Next expected readout: November 2026 · NCT06705764 (registry estimate)
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: AZD8630's landscape · tezepelumab's landscape